Aldeyra Therapeutics (FRA:137) FFO


FRA:137 Aldeyra Therapeutics Inc FRA:137
29 GF Score
Price €1.63
! 2 Warning Signs
View Full Analysis

What is Aldeyra Therapeutics FFO?

FFO (Funds from operations) only applies to REITs.

FRA:137
29GF Score
Aldeyra Therapeutics Inc FRA:137
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aldeyra Therapeutics Business Description

Other Exchanges ALDX:USA137:Germany
Address 131 Hartwell Avenue, Suite 320, Lexington, MA, USA, 02421
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
29GF Score

Get the complete analysis for FRA:137

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.63
Price